France Continuous Glucose Monitoring Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Application (Diabetic Patients, Critical Patients), And By End User Industry (Hospitals, Diagnostic Centers And Clinics, Home Care) - Forecasts From 2023 To 2028
- Published : Apr 2023
- Report Code : KSI061614933
- Pages : 78
The France Continuous Glucose Monitoring Market is projected to grow at a CAGR of 17.38% during the forecast period to reach US$278.016 million by 2028, from US$90.580 million in 2021.
Continuous glucose monitoring or CGM is a wearable medical device that continuously tracks blood sugar levels for people with type 1 and type 2 diabetes. Tracking blood sugar levels is extremely essential for diabetic patients as they have to make sure when to take insulin and CGM devices help them in determining that. CGM is a widely used technology as it is advantageous for diabetics. Studies have shown that the use of CGM devices ensures a shorter duration of hypoglycemia or a lower level of glycated haemoglobin. In France, the continuous glucose monitoring market is segmented by application and end-user.
The growing prevalence of type 1 and type 2 diabetes, continuous product launches by key market players along with rising government initiatives and programmes to educate people about diabetic health & care are some of the key determinants which are positively impacting the demand for CGM devices in this country.
During the anticipation period, the growing incidences of diabetes will support the growth of the French continuous glucose monitoring market during the projection period.
One of the primary factors driving the growth of continuous glucose monitoring devices in France is the high prevalence of type 1 and type 2 diabetes among the population. According to the statistics presented by the International Diabetes Federation, 8.6 per cent of French adults, or more than 3.9 million people, have diabetes in 2021. This number is expected to reach 4.2 million by 2045. Moreover, 4.8 million people have impaired glucose tolerance in this country, which puts them at a greater risk of becoming type 2 diabetes. This number is anticipated to reach 4.9 million by 2045. Those who have diabetes run the risk of significant and fatal consequences like heart attack, kidney failure, blindness, and lower limb amputation. This leads to a lower quality of life and higher medical expenditure. The prevalence of diabetes has alarmingly increased across France in recent years, reaching an all-time high mostly due to lifestyle changes. Diabetes is also one of the leading causes of death in France. According to IDF data, nearly 87 thousand died due to diabetes. Diabetic patients must make several adjustments throughout the day to keep their blood glucose levels within acceptable ranges. Therefore CGM devices are extremely crucial for them. The decreasing cost of CGM devices in the country is also propelling market demand.
Various policies, programs and services related to diabetes by the government and increasing CGM reimbursement to spur growth during the projection period.
To combat risk factors like obesity and other medical conditions, the French government has implemented several reforms over the years to improve the distribution of doctors, create new types of service organisations, introduce new financing models, and implement a variety of quality improvement initiatives and policy frameworks in the healthcare sector. This also emphasizes chances for sustaining and growing advancements in the provision of diabetes care and the application of diabetes technologies. Initiatives implemented by the French government are anticipated to fuel the market's expansion.
In April 2020, the French National Authority for Health announced the decision to provide medical assistance reimbursement of several medical devices to all French citizens which include DEXCOM G6, a continuous glucose monitoring system. The French Health Ministry granted national reimbursement for FreeStyle® Libre, Abbott's ground-breaking glucose monitoring system throughout France. This reimbursement policy will provide access to the FreeStyle Libre system to all French citizens suffering from Type 1 and Type 2 diabetes who take insulin more than once per day.
Market Key Developments
- In May 2022, DexCom announced that their G7 CGM system, designed for people with diabetes who are two years of age and older, including pregnant women, has received the CE Mark in Europe. With this certification, the most widely used real-time CGM in the world is now more powerful and user-friendly thanks to a compact, all-in-one wearable design and a newly revamped mobile app.
- In October 2022, Dexcom introduced the Dexcom G7, a next-generation continuous glucose monitor (CGM), for diabetics two years of age and above. The Dexcom G7 improves on the Dexcom CGM by adding new features such as a 60 % smaller, all-in-one, discrete wearable and the quickest 30-minute sensor warm-up of any CGM on the market.
- In March 2022, Glooko Inc a leading provider of remote patient monitoring and data management solutions for diabetes and related chronic conditions announced the acquisition of DIABNEXT, a Paris-based company with a digital health platform that helps people with diabetes better manage their conditions. The primary reason for the acquisition is the expansion of Glooko Inc diabetes offerings in France.
- By Application
- Diabetes Patients
- Critical Patients
- By End User
- Diagnostic Centers & Clinics
- Home Care
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.7. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Data
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Force Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. FRANCE CONTINUOUS GLUCOSE MONITORING (CGM) MARKET, BY APPLICATION
5.2. Diabetes Patients
5.3. Critical Patients
6. FRANCE CONTINUOUS GLUCOSE MONITORING (CGM) MARKET, BY END-USER INDUSTRY
6.3. Diagnostic Centers & Clinics
6.4. Home Care
7. COMPETITIVE ENVIRONMENT AND ANALYSIS
7.1. Major Players and Strategy Analysis
7.2. Emerging Players and Market Lucrativeness
7.3. Mergers, Acquisitions, Agreements, and Collaborations
7.4. Vendor Competitiveness Matrix
8. COMPANY PROFILES
8.1. Dexcom, Inc.
8.2. Abbott Laboratories
8.3. Medtronic plc
8.4. Roche Diabetes Care, Inc.
8.5. Ascensia Diabetes Care
8.6. Insulet Corporation
8.7. Tandem Diabetes Care, Inc.
Roche Diabetes Care, Inc.
Ascensia Diabetes Care
Tandem Diabetes Care, Inc.
|Report Name||Published Month||Get Sample PDF|